ACTIVE_NOT_RECRUITING

Effect of Rapamycin in Ovarian Aging

Description

The investigators are proposing a prospective, randomized, double-blind, placebo-controlled pilot study assessing the ability of low-dose rapamycin to delay ovarian aging in women. Animal studies have shown the potential of rapamycin in slowing or reversing some age-associated pathways.

Conditions

Perimenopausal
Talk to us

Related Conditions:

Perimenopausal

Study Overview

On this page

Study Details

Study overview

The investigators are proposing a prospective, randomized, double-blind, placebo-controlled pilot study assessing the ability of low-dose rapamycin to delay ovarian aging in women. Animal studies have shown the potential of rapamycin in slowing or reversing some age-associated pathways.

Effect of Rapamycin in Ovarian Aging

Effect of Rapamycin in Ovarian Aging

Condition
Perimenopausal
Intervention / Treatment

-

Contacts and Locations

New York

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States, 10032

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Women aged 35-45 years
  • * In the menopausal transition stage -3a
  • * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years
  • * Have regular menstrual periods (with less than 7 days of variability)
  • * Early follicular phase follicle stimulating hormone (FSH) levels \] \< 20 mIU/mL
  • * Anti-müllerian hormone (AMH) levels of \>0.1 ng/mL
  • * Antral Follicle Counts (AFC) of \>3
  • * Women with irregular menstrual cycles
  • * Severe ovarian deficiency, or with no evidence of remaining follicles
  • * Kidney or liver disease
  • * Any significant medical disease, including cancer
  • * Contraindications to receiving rapamycin

Ages Eligible for Study

35 Years to 45 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Columbia University,

Samuel Z. Williams, MD, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

2026-09